Crucell 2008
Combating Infectious Diseases
Annual Report and Form 20–F

• What Corporate Social Responsibility means to us
• What we do
• A CSR dilemma
• Crucell on its mission to combat infectious diseases
• Who we work with
• An example: Warm response to cold chain training
• How we do business
• A partnership with customers illustrated
• Crucell's PER.C6^® technology
• How we see our responsibility
• Crucell works in an environment that requires highly skilled employees
• Innovative safety approach
• Beyond legislation for safety
• Environmental impact
• An example: Combining vaccines for a diversity of benefits
• Energy & water consumption
• Economic aspects of our business

An example: Combining vaccines for a diversity of benefits

Crucell’s development of the pentavalent vaccine Quinvaxem^® is a good example of how we are working to increase vaccination coverage and save lives in countries where healthcare resources are less than optimal. Quinvaxem^® is a fully liquid vaccine combining antigens for protection against five potentially deadly childhood diseases: diphtheria, tetanus, pertussis (whooping cough), hepatitis B, and Haemophilus influenzae type B. As the first internationally available fully liquid vaccine containing all five of these antigens, Quinvaxem^® offers major healthcare advantages, particularly for low‑income countries with infrastructure and hygiene problems. The fully liquid, single-vial formulation of Quinvaxem^® reduces waste and decreases the risk of contamination compared to products requiring reconstitution, as well as being more convenient. And because five antigens are delivered in a single shot, fewer injections and visits to a clinic are necessary. This greatly increases the chance that children will receive protection against important diseases. Supranational organizations have awarded Crucell contracts worth $0.5 billion to supply Quinvaxem^®, confirming the superior quality of our pentavalent vaccine, of which over half had been sold by the end of 2008. The remainder is expect to be sold in 2009. Quinvaxem^® was launched end 2006 and has a market share of over 50% already. Currently Crucell is working on developing a hexavalent vaccine.